Litigation Watch: Top focus names for Q3
MDC follows significant legal disputes to provide clients with actionable investment ideas. Focus List situations that they believe may be among the most actionable during Q3 include Burford Capital, Reckitt Benckiser and Bayer. Burford is a UK based litigation funder that has already been awarded a Judgment totalling $16,099,788,293. Now, the challenge is to collect from the Republic of Argentina! Reckitt along with Abbott Laboratories are facing product liability lawsuits in the US regarding baby formula products causing NEC. The next bellwether trial will be in the Diggs Case scheduled to start on Aug 8th. As if Bayer hasn't faced enough toxic tort litigation regarding its Roundup weed killer product, it now faces potential liability for Polychlorinated Biphenyls. The next PCB Trial is scheduled to commence on Sep 8th.
Edition: 215
- 11 July, 2025
Event-Driven Legal℠ investment-research opportunities
MDC follows significant legal disputes to provide clients with actionable investment ideas that tend to be non-correlated with the market. They currently believe that the following companies will likely be involved in significant litigation in 2025 and 2026: Abbott Laboratories, Avadel Pharmaceuticals, Axsome Therapeutics, Bausch Health, Bayer, Burford Capital, Corcept Therapeutics, Exelixis, GSK, Harmony Biosciences, Johnson & Johnson, Liquidia, Live Nation, Reckitt and Sotera Health.
Edition: 205
- 21 February, 2025
Materials
This mining services company provides drilling, laboratory and waste haulage services to blue-chip firms. CAPD boasts higher margins than its competitors and has maintained these margins with significant growth over the last 2 years. Ben Jones forecasts EBT margins of ~20% going forward with FCF yield of 25% by 2025. Current trading is strong, having recently signed new drilling and laboratory contracts which Ben expects to add 11% to revenue growth in 2023 and 17% in revenue growth in 2024. The market is failing to price in this growth leaving a wide gap between CAPD’s M/Cap and Ben’s view of intrinsic value.
Edition: 177
- 12 January, 2024